Novartis teams up with Oxford researchers to crunch big data into clinical insights
Since Vas Narasimhan’s Day 1 as CEO of Novartis, he has championed data science and digital technologies as a key priority at the pharma giant. Almost a year into his tenure, in a recent conversation with the tech VC firm Andreessen Horowitz, he highlighted the abilities to analyze pathology images and centralize clinical trial planning as two promising applications of machine learning.
But, he admitted, there are areas where it’s “simply not met up”:
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters